Evidence map›Paper›PMID 28418843›Full record

ArticleOncotarget2017

CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer.

Xinyu Deng, Sophia Apple, Hong Zhao, Jeongyoon Song, Minna Lee, William Luo, Xiancheng Wu, Debra Chung, Richard J Pietras, Helena R Chang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  6. Review
  7. Profiling of Breast Cancer Stem Cell Types/States Shows the Role of CD44International journal of molecular sciences · 2025
    Article
  8. Protein Marker-Dependent Drug Discovery Targeting Breast Cancer Stem Cells.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Targeting CD24 as a novel immunotherapy for solid cancers.Cell communication and signaling : CCS · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Xinyu DengGonda, UCLA Breast Cancer Research Laboratory and Revlon, UCLA Breast Center, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-7028, USA.
Sophia ApplePathology and Laboratory Medicine, University of California, Los Angeles, CA 90095-1732, USA.
Hong ZhaoGonda, UCLA Breast Cancer Research Laboratory and Revlon, UCLA Breast Center, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-7028, USA.
Jeongyoon SongGonda, UCLA Breast Cancer Research Laboratory and Revlon, UCLA Breast Center, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-7028, USA.
Minna LeeGonda, UCLA Breast Cancer Research Laboratory and Revlon, UCLA Breast Center, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-7028, USA.
William LuoGonda, UCLA Breast Cancer Research Laboratory and Revlon, UCLA Breast Center, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-7028, USA.
Xiancheng WuGonda, UCLA Breast Cancer Research Laboratory and Revlon, UCLA Breast Center, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-7028, USA.
Debra ChungGonda, UCLA Breast Cancer Research Laboratory and Revlon, UCLA Breast Center, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-7028, USA.
Richard J PietrasDepartment of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1678, USA.
Helena R ChangGonda, UCLA Breast Cancer Research Laboratory and Revlon, UCLA Breast Center, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-7028, USA.
Breast Cancer Research Foundation · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is a leading cause of cancer-related death in women. Adjuvant systemic chemotherapies are effective in reducing risks of recurrence and have contributed to reduced BC mortality. Although targeted adjuvant treatments determined by biomarkers for endocrine and HER2-directed therapies are largely successful, predicting clinical benefit from chemotherapy is more challenging. Drug resistance is a major reason for treatment failures. Efforts are ongoing to find biomarkers to select patients most likely to benefit from chemotherapy. Importantly, cell surface biomarkers CD44+/CD24- are linked to drug resistance in some reports, yet underlying mechanisms are largely unknown. This study focused on the potential role of CD24 expression in resistance to either docetaxel or doxorubicin in part by the use of triple-negative BC (TNBC) tissue microarrays. In vitro assays were also done to assess changes in CD24 expression and differential drug susceptibility after chemotherapy. Further, mouse tumor xenograft studies were done to confirm in vitro findings. Overall, the results show that patients with CD24-positive TNBC had significantly worse overall survival and disease-free survival after taxane-based treatment. Also, in vitro cell studies show that CD44+/CD24+/high cells are more resistant to docetaxel, while CD44+/CD24-/low cells are resistant to doxorubicin. Both in vitro and in vivo studies show that cells with CD24-knockdown are more sensitive to docetaxel, while CD24-overexpressing cells are more sensitive to doxorubicin. Further, mechanistic studies indicate that Bcl-2 and TGF-βR1 signaling via ATM-NDRG2 pathways regulate CD24. Hence, CD24 may be a biomarker to select chemotherapeutics and a target to overcome TNBC drug resistance.

Indexed as

Drug Resistance, NeoplasmTriple Negative Breast NeoplasmsAnimalsBiomarkers, TumorCD24 AntigenCell Line, TumorDisease-Free SurvivalFemaleHeterograftsHumansKaplan-Meier EstimateMiceBiomarkers, TumorCD24 AntigenCD24 protein, humanbreast cancerCD24chemotherapydrug resistanceEMT

Identifiers

PMID28418843
PMCPMC5503533
OpenAlexW2597426974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.